Semax research brings together experiments that answer different questions. A useful overview keeps the model, measurement and uncertainty next to each finding.
Selected evidence by study type
| Source | Model and measurement | Limit to preserve |
|---|---|---|
| Dolotov et al., 2006 | Rat hippocampal BDNF/trkB measurements and a behavioural task | Animal findings are not a general human cognitive outcome |
| Medvedeva et al., 2017 | Gene-expression analysis in rats with experimental cerebral ischaemia | Model-specific transcript changes do not establish clinical recovery |
| Human imaging study, 2018 | Resting-state fMRI in 24 healthy volunteers | An imaging change is not the same endpoint as sustained cognitive improvement |
Read mechanism findings within the experiment
The 2006 rat study reported changes in hippocampal BDNF-related measures. The 2017 work examined gene expression after experimental ischaemia and implicated immune-response processes. These papers can inform mechanistic questions, but their findings should retain the species, intervention and laboratory setting.
What the human imaging paper can support
The 2018 study compared 14 participants receiving Semax with 10 receiving placebo and measured resting-state brain-network patterns shortly after administration. It reported a difference in a default-mode-network component. Its small sample and imaging endpoint matter when interpreting the result; the experiment was not a demonstration of a broad long-term cognitive benefit.
Questions for a stronger evidence summary
- Was the material and formulation clearly identified?
- Were the findings independently replicated in a comparable model?
- Did the experiment measure the outcome claimed in the summary?
- Are adverse findings and uncertainty retained?
- Does a human study actually address the population and time period of interest?
Connect evidence with identity
A label on a research vial does not establish equivalence to a study preparation. Use the analytical report guide for batch-document interpretation. The neuropeptide research topic links related compounds while preserving their separate identities.
This is a guide to selected primary studies, not a systematic review or a complete current trial registry. The editorial standards explain the evidence labels and correction process.
BDNF is a signalling result, not an intelligence score
BDNF is a neurotrophin, a protein involved in neuronal support and signalling; TrkB is one of its receptors. In a 2006 rat study, Semax increased selected hippocampal BDNF and TrkB measurements and changed performance in a conditioned-avoidance task. The hippocampus is a brain structure involved in learning and memory.
The important distinction is between the molecular measurement and the behavioural task. A larger BDNF-related signal does not come with a universal conversion into memory improvement, and a rat's learned response in one task does not establish better concentration in a healthy person.
Immune effects depend on the injury model
The 2017 cerebral-ischaemia experiment analysed gene expression in rat cortex following an interruption of blood supply. Semax affected immune-response pathways, including antigen presentation and interferon-related signalling. This was not simply a uniform decrease in all inflammatory activity.
That nuance matters because inflammation is a collection of responses with different roles and timing. Changes in RNA abundance suggest which processes may be involved; they do not establish corresponding protein activity or a clinical stroke-recovery benefit. The authors proposed further work on the proteins underlying the responses.
What the small human scan study actually measured
The 2018 resting-state imaging study included 24 healthy volunteers: 14 received Semax and 10 placebo. Scans were taken before exposure and five and twenty minutes afterwards. The reported difference concerned the extent of a frontal component of the default-mode network, a pattern identified while participants were not performing a specific task.
This is a short-term imaging result. It is not a memory test, a demonstration of improved productivity or evidence of new brain tissue. A difference in the extent of a functionally defined network should not be described as anatomical brain growth.
Connectivity findings need functional follow-through
A 2020 report in 52 healthy participants compared Semax, Selank and placebo using brain-region connectivity measurements. It identified effects involving the right amygdala and temporal regions. It should not be counted automatically as an entirely independent replication of the earlier work without checking participant overlap and methods.
Both reports are useful for generating hypotheses about network activity. A stronger claim about everyday cognition would need prespecified cognitive outcomes, adequate controls, sustained follow-up and adverse-event assessment. The bridge from a changing scan to a meaningful benefit has to be tested rather than assumed.
